Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook
In BriefThis Month in JNM

This Month in JNM

Journal of Nuclear Medicine August 2015, 56 (8) 8A;
  • Article
  • Info & Metrics
  • PDF
Loading

PSMA PET in prostate cancer: Jadvar provides perspective on prostate-specific membrane antigen as a biomarker in imaging evaluation of prostate cancer and previews a study on this topic in this issue of JNM.

Page 1131

Quantitative accuracy of PET/CT: Kinahan and colleagues look at the increasing need for precision results in PET/CT assessment of tumor response to therapy and introduce a related article in this issue of JNM.

Page 1133

Imaging T cells: Neri describes current efforts and challenges in imaging T cells in vivo and outlines the novel biomedical opportunities afforded by this capability.

Page 1135

PET/CT repeatability in NSCLC: Weber and colleagues explore the repeatability of quantitative parameters derived from 18F-FDG PET/CT imaging in non–small cell lung cancer and discuss the application of these results in monitoring tumor response to therapy.

Page 1137

PET and tumor fluid penetrance: Lubberink and colleagues assess the effects of imatinib and anakinra on perfusable tissue fraction and tumor blood flow in colorectal cancer metastases using 15O-water PET/CT and kinetic modeling.

Page 1144

Prognosis and pretherapeutic SUR: Bütof and colleagues investigate whether 18F-FDG PET imaging can provide independent prognostic information in patients with inoperable esophageal carcinoma and whether the tumor-to-blood standard uptake ratio can enhance the quality of this information.

Page 1150

Intraarterial hepatic SPECT/CT: Gates and colleagues demonstrate typical and atypical findings of 99mTc-MAA distribution on SPECT/CT obtained as part of pretherapeutic planning for radioembolization with 90Y microspheres.

Page 1157

PET/CT in pancreatic cysts: Kauhanen and colleagues compare the accuracies of combined 18F-FDG PET and contrast-enhanced CT, multidetector CT, and MR imaging in differentiating malignant from benign pancreatic cysts.

Page 1163

68Ga-/177Lu-PSMA theranostics: Weineisen and colleagues describe development, preclinical evaluation, and proof-of-concept investigation of a prostate-specific membrane antigen inhibitor for imaging and therapy in patients with metastatic and castration-resistant prostate cancer.

Page 1169

PET/CT and survival after 223Ra: Etchebehere and colleagues evaluate outcomes after 223Ra-diochloride therapy for hormone-refractory prostate cancer and determine whether skeletal tumor burden on whole-body 18F-fluoride PET/CT is prognostic for survival.

Page 1177

18F-fluoromethylcholine vs. 68Ga-PSMA: Morigi and colleagues compare the detection rates of a 68Ga-prostate-specific membrane antigen agent and 18F-fluoromethylcholine in PET/CT in men initially managed with radical prostatectomy, radiation treatment, or both who were being considered for targeted therapy.

Page 1185

PET/CT, MTV, and endometrial cancer: Husby and colleagues explore the value of 18F-FDG PET/CT for preoperative staging in endometrial carcinomas and the correspondence of 18F-FDG PET–specific quantitative tumor parameters, including metabolic tumor volumes, to clinical and histologic characteristics.

Page 1191

PiB R1 as CBF proxy: Chen and colleagues assess the suitability of 11C-Pittsburgh compound B blood–brain barrier delivery and relative delivery parameters as surrogate indices of cerebral blood flow in mild cognitive impairment and Alzheimer disease.

Page 1199

Red nucleus metabolic activity: Hirata and colleagues use a high-resolution semiconductor PET system to investigate the metabolism of the human red nucleus and its correlation to other brain regions.

Page 1206

Current practices in V/Q scintigraphy: Le Roux and colleagues survey current clinical standards of practice in Australia, Canada, and France for ventilation/perfusion imaging in evaluation of suspected acute pulmonary embolism.

Page 1212

Fetal 18F-FDG dosimetry: Zanotti-Fregonara and colleagues estimate fetal radiation doses from 18F-FDG in a series of pregnant women who underwent PET imaging during clinical workup for malignancies.

Page 1218

Quantitative imaging of hypoxia: Muzi and colleagues test the validity of using image-derived tissue regions that are highly correlated to blood levels as an alternative to serial blood sampling in 18F-FMISO PET assessment of hypoxia.

Page 1223

Upper gastrointestinal motility studies: Maurer provides the first of 2 educational overviews of gastrointestinal scintigraphy, focusing here on esophageal transit and gastric emptying.

Page 1229

RIT with cetuximab in CRC: Vassileva and colleagues evaluate the preclinical efficacy of combination radioimmunotherapy, using a humanized 131I-labeled anti-carcinoembryonic antigen antibody and cetuximab in colorectal cancer.

Page 1239

Imaging periostin for cancer invasion: Heidari and colleagues develop and characterize a PET tracer that specifically targets the extracellular matrix protein periostin and evaluate this probe in preclinical models of esophageal squamous cell carcinoma.

Page 1246

TBI and 64CuCl2 PET/CT: Peng and colleagues report on the potential of this copper-based PET imaging agent as a biomarker for experimental traumatic brain injury in mice.

Page 1252

Immuno-PET and T cell reconstitution: Tavaré and colleagues detail the generation of anti-CD4 and -CD8 cys-diabodies derived from parental antibody hybridomas for 89Zr-immuno-PET detection of helper and cytotoxic T cell populations.

Page 1258

PET and tumor-associated macrophages: Blykers and colleagues explore the identification and 18F-labeled antibody fragment PET assessment of M2-oriented tumor-supporting macrophages within the tumor microenvironment as indicators of cancer progression and prognosis.

Page 1265

89Zr-HDL tumor-associated macrophage imaging: Pérez-Medina and colleagues describe the development of reconstituted high-density lipoprotein-facilitated tumor-associated macrophage PET imaging in a preclinical breast cancer model.

Page 1272

PET/NIRF assessment of quantum dots: Hu and colleagues report on a dual receptor–targeting dual-modality PET/near-infrared fluorescence probe for accurate assessment of the pharmacokinetics and tumor-targeting efficacy of semiconductor quantum dots.

Page 1278

Isotopes, image quality, and hybrid scanners: Soderlund and colleagues investigate image quality for 18F, 11C, 89Zr, 124I, 68Ga, and 90Y on PET/CT and PET/MR clinical scanners.

Page 1285

  • © 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 56 (8)
Journal of Nuclear Medicine
Vol. 56, Issue 8
August 1, 2015
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
This Month in JNM
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
This Month in JNM
Journal of Nuclear Medicine Aug 2015, 56 (8) 8A;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
This Month in JNM
Journal of Nuclear Medicine Aug 2015, 56 (8) 8A;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • In Vivo Cancer Dual-Targeting and Dual-Modality Imaging with Functionalized Quantum Dots
  • Significant Therapeutic Efficacy with Combined Radioimmunotherapy and Cetuximab in Preclinical Models of Colorectal Cancer
  • Pulmonary Scintigraphy for the Diagnosis of Acute Pulmonary Embolism: A Survey of Current Practices in Australia, Canada, and France
  • Metabolic Tumor Volume on 18F-FDG PET/CT Improves Preoperative Identification of High-Risk Endometrial Carcinoma Patients
  • Relative 11C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session 15O-Water and 11C-PiB PET
  • Fetal Radiation Dose from 18F-FDG in Pregnant Patients Imaged with PET, PET/CT, and PET/MR
  • Imaging T Cells In Vivo
  • Intraarterial Hepatic SPECT/CT Imaging Using 99mTc-Macroaggregated Albumin in Preparation for Radioembolization
  • Prognostic Value of Pretherapeutic Tumor-to-Blood Standardized Uptake Ratio in Patients with Esophageal Carcinoma
  • Beyond 18F-FDG: Characterization of PET/CT and PET/MR Scanners for a Comprehensive Set of Positron Emitters of Growing Application—18F, 11C, 89Zr, 124I, 68Ga, and 90Y
  • Metabolic Activity of Red Nucleus and Its Correlation with Cerebral Cortex and Cerebellum: A Study Using a High-Resolution Semiconductor PET System
  • 15O-Water PET Study of the Effect of Imatinib, a Selective Platelet-Derived Growth Factor Receptor Inhibitor, Versus Anakinra, an IL-1R Antagonist, on Water-Perfusable Tissue Fraction in Colorectal Cancer Metastases
  • 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies
  • PSMA PET in Prostate Cancer
  • Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy
  • The Value of Establishing the Quantitative Accuracy of PET/CT Imaging
  • PET Imaging of Macrophage Mannose Receptor–Expressing Macrophages in Tumor Stroma Using 18F-Radiolabeled Camelid Single-Domain Antibody Fragments
  • Repeatability of 18F-FDG PET/CT in Advanced Non–Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials
  • 18F-Fluoromisonidazole Quantification of Hypoxia in Human Cancer Patients Using Image-Derived Blood Surrogate Tissue Reference Regions
  • Accuracy of 18F-FDG PET/CT, Multidetector CT, and MR Imaging in the Diagnosis of Pancreatic Cysts: A Prospective Single-Center Study
  • Imaging of Secreted Extracellular Periostin, an Important Marker of Invasion in the Tumor Microenvironment in Esophageal Cancer
  • PET Imaging of Tumor-Associated Macrophages with 89Zr-Labeled High-Density Lipoprotein Nanoparticles
  • Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival
  • Gastrointestinal Motility, Part 1: Esophageal Transit and Gastric Emptying
  • Assessment of Traumatic Brain Injury by Increased 64Cu Uptake on 64CuCl2 PET/CT
  • Immuno-PET of Murine T Cell Reconstitution Postadoptive Stem Cell Transplantation Using Anti-CD4 and Anti-CD8 Cys-Diabodies
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • This Month in JNM
  • This Month in JNM
  • This Month in JNM
Show more This Month in JNM

Similar Articles

SNMMI

© 2021 Journal of Nuclear Medicine

Powered by HighWire